GH1 and type 2 diabetes mellitus: Because GH has been shown to worsen glucose tolerance in some subjects, including those receiving highly active antiretroviral therapy (HAART) [11], a randomized, parallel, placebo-controlled, multicenter study was carried out to assess the safety of tesamorelin in only subjects with type 2 diabetes mellitus.